The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global BRAF Kinase Inhibitors Market Research Report 2025
Synopsis
BRAF kinase inhibitors are generally used as targeted therapy drugs for the treatment of carcinomas such as RCC, NSCLC, and melanomas caused by mutations of the BRAF gene.
The global BRAF Kinase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
These drugs directly target BRAF protein and inhibit the growth of tumors in patients with metastatic melanoma. Such results delivered by the BRAF kinase inhibitors has encouraged several R&D teams to extend research on other applications. Moreover, many BRAF kinase inhibitor drugs are in the final stages of development and are expected to be launched during the forecast period.
This report aims to provide a comprehensive presentation of the global market for BRAF Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding BRAF Kinase Inhibitors.
Report Scope
The BRAF Kinase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Liter) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global BRAF Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the BRAF Kinase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Array BioPharma Inc.
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Segment by Type
Dabrafenib
Sorafenib
Vemurafenib
Encorafenib
Segment by Application
Hospital
Medical Research Institute
Clinic
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of BRAF Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of BRAF Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
BRAF kinase inhibitors are generally used as targeted therapy drugs for the treatment of carcinomas such as RCC, NSCLC, and melanomas caused by mutations of the BRAF gene.
The global BRAF Kinase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
These drugs directly target BRAF protein and inhibit the growth of tumors in patients with metastatic melanoma. Such results delivered by the BRAF kinase inhibitors has encouraged several R&D teams to extend research on other applications. Moreover, many BRAF kinase inhibitor drugs are in the final stages of development and are expected to be launched during the forecast period.
This report aims to provide a comprehensive presentation of the global market for BRAF Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding BRAF Kinase Inhibitors.
Report Scope
The BRAF Kinase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Liter) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global BRAF Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the BRAF Kinase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Array BioPharma Inc.
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG
Segment by Type
Dabrafenib
Sorafenib
Vemurafenib
Encorafenib
Segment by Application
Hospital
Medical Research Institute
Clinic
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of BRAF Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of BRAF Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 BRAF Kinase Inhibitors Market Overview
1.1 Product Overview and Scope of BRAF Kinase Inhibitors
1.2 BRAF Kinase Inhibitors Segment by Type
1.2.1 Global BRAF Kinase Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Dabrafenib
1.2.3 Sorafenib
1.2.4 Vemurafenib
1.2.5 Encorafenib
1.3 BRAF Kinase Inhibitors Segment by Application
1.3.1 Global BRAF Kinase Inhibitors Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Medical Research Institute
1.3.4 Clinic
1.3.5 Other
1.4 Global BRAF Kinase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global BRAF Kinase Inhibitors Revenue 2019-2030
1.4.2 Global BRAF Kinase Inhibitors Sales 2019-2030
1.4.3 Global BRAF Kinase Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 BRAF Kinase Inhibitors Market Competition by Manufacturers
2.1 Global BRAF Kinase Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global BRAF Kinase Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global BRAF Kinase Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global BRAF Kinase Inhibitors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of BRAF Kinase Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of BRAF Kinase Inhibitors, Product Type & Application
2.7 BRAF Kinase Inhibitors Market Competitive Situation and Trends
2.7.1 BRAF Kinase Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest BRAF Kinase Inhibitors Players Market Share by Revenue
2.7.3 Global BRAF Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 BRAF Kinase Inhibitors Retrospective Market Scenario by Region
3.1 Global BRAF Kinase Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global BRAF Kinase Inhibitors Global BRAF Kinase Inhibitors Sales by Region: 2019-2030
3.2.1 Global BRAF Kinase Inhibitors Sales by Region: 2019-2024
3.2.2 Global BRAF Kinase Inhibitors Sales by Region: 2025-2030
3.3 Global BRAF Kinase Inhibitors Global BRAF Kinase Inhibitors Revenue by Region: 2019-2030
3.3.1 Global BRAF Kinase Inhibitors Revenue by Region: 2019-2024
3.3.2 Global BRAF Kinase Inhibitors Revenue by Region: 2025-2030
3.4 North America BRAF Kinase Inhibitors Market Facts & Figures by Country
3.4.1 North America BRAF Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America BRAF Kinase Inhibitors Sales by Country (2019-2030)
3.4.3 North America BRAF Kinase Inhibitors Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe BRAF Kinase Inhibitors Market Facts & Figures by Country
3.5.1 Europe BRAF Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe BRAF Kinase Inhibitors Sales by Country (2019-2030)
3.5.3 Europe BRAF Kinase Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific BRAF Kinase Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific BRAF Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific BRAF Kinase Inhibitors Sales by Country (2019-2030)
3.6.3 Asia Pacific BRAF Kinase Inhibitors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America BRAF Kinase Inhibitors Market Facts & Figures by Country
3.7.1 Latin America BRAF Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America BRAF Kinase Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America BRAF Kinase Inhibitors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa BRAF Kinase Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa BRAF Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa BRAF Kinase Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa BRAF Kinase Inhibitors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global BRAF Kinase Inhibitors Sales by Type (2019-2030)
4.1.1 Global BRAF Kinase Inhibitors Sales by Type (2019-2024)
4.1.2 Global BRAF Kinase Inhibitors Sales by Type (2025-2030)
4.1.3 Global BRAF Kinase Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global BRAF Kinase Inhibitors Revenue by Type (2019-2030)
4.2.1 Global BRAF Kinase Inhibitors Revenue by Type (2019-2024)
4.2.2 Global BRAF Kinase Inhibitors Revenue by Type (2025-2030)
4.2.3 Global BRAF Kinase Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global BRAF Kinase Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global BRAF Kinase Inhibitors Sales by Application (2019-2030)
5.1.1 Global BRAF Kinase Inhibitors Sales by Application (2019-2024)
5.1.2 Global BRAF Kinase Inhibitors Sales by Application (2025-2030)
5.1.3 Global BRAF Kinase Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global BRAF Kinase Inhibitors Revenue by Application (2019-2030)
5.2.1 Global BRAF Kinase Inhibitors Revenue by Application (2019-2024)
5.2.2 Global BRAF Kinase Inhibitors Revenue by Application (2025-2030)
5.2.3 Global BRAF Kinase Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global BRAF Kinase Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Array BioPharma Inc.
6.1.1 Array BioPharma Inc. Corporation Information
6.1.2 Array BioPharma Inc. Description and Business Overview
6.1.3 Array BioPharma Inc. BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Array BioPharma Inc. BRAF Kinase Inhibitors Product Portfolio
6.1.5 Array BioPharma Inc. Recent Developments/Updates
6.2 Bayer AG
6.2.1 Bayer AG Corporation Information
6.2.2 Bayer AG Description and Business Overview
6.2.3 Bayer AG BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer AG BRAF Kinase Inhibitors Product Portfolio
6.2.5 Bayer AG Recent Developments/Updates
6.3 F. Hoffmann-La Roche Ltd.
6.3.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.3.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.3.3 F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 F. Hoffmann-La Roche Ltd. BRAF Kinase Inhibitors Product Portfolio
6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG BRAF Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG BRAF Kinase Inhibitors Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 BRAF Kinase Inhibitors Industry Chain Analysis
7.2 BRAF Kinase Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 BRAF Kinase Inhibitors Production Mode & Process
7.4 BRAF Kinase Inhibitors Sales and Marketing
7.4.1 BRAF Kinase Inhibitors Sales Channels
7.4.2 BRAF Kinase Inhibitors Distributors
7.5 BRAF Kinase Inhibitors Customers
8 BRAF Kinase Inhibitors Market Dynamics
8.1 BRAF Kinase Inhibitors Industry Trends
8.2 BRAF Kinase Inhibitors Market Drivers
8.3 BRAF Kinase Inhibitors Market Challenges
8.4 BRAF Kinase Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
